Cargando…

An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.

The U.S. Food and Drug Administration (FDA) created the GenomeTrakr Whole Genome Sequencing (WGS) Network in 2013, as a tool to improve food safety. This study presents an analysis of Whole Genome source tracking implementation on potential food contamination and related illnesses through theoretica...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Brad, Allard, Marc, Bazaco, Michael C., Blankenship, Joseph, Minor, Travis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494326/
https://www.ncbi.nlm.nih.gov/pubmed/34614029
http://dx.doi.org/10.1371/journal.pone.0258262
_version_ 1784579287746084864
author Brown, Brad
Allard, Marc
Bazaco, Michael C.
Blankenship, Joseph
Minor, Travis
author_facet Brown, Brad
Allard, Marc
Bazaco, Michael C.
Blankenship, Joseph
Minor, Travis
author_sort Brown, Brad
collection PubMed
description The U.S. Food and Drug Administration (FDA) created the GenomeTrakr Whole Genome Sequencing (WGS) Network in 2013, as a tool to improve food safety. This study presents an analysis of Whole Genome source tracking implementation on potential food contamination and related illnesses through theoretical, empirical, and cost benefit analyses. We conduct empirical tests using data from FDA regulated food commodity outbreaks garnering FDA response from 1999 through 2019 and examine the effect of the National Center for Biotechnology Information (NCBI) Pathogen detection program of source tracking WGS isolates collected in the U.S. on outbreak illnesses for three pilot pathogens (E. coli, Listeria, and Salmonella). Empirical results are consistent with the theoretical model and suggest that each additional 1,000 WGS isolates added to the public NCBI database is associated with a reduction of approximately 6 illnesses per WGS pathogen, per year. Empirical results are connected to existing literature for a Monte Carlo analysis to estimate benefits and costs. By 2019, annual health benefits are estimated at nearly $500 million, compared to an approximately $22 million investment by public health agencies. Even under conservative assumptions, the program likely broke even in its second year of implementation and could produce increasing public health benefits as the GenomeTrakr network matures.
format Online
Article
Text
id pubmed-8494326
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-84943262021-10-07 An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S. Brown, Brad Allard, Marc Bazaco, Michael C. Blankenship, Joseph Minor, Travis PLoS One Research Article The U.S. Food and Drug Administration (FDA) created the GenomeTrakr Whole Genome Sequencing (WGS) Network in 2013, as a tool to improve food safety. This study presents an analysis of Whole Genome source tracking implementation on potential food contamination and related illnesses through theoretical, empirical, and cost benefit analyses. We conduct empirical tests using data from FDA regulated food commodity outbreaks garnering FDA response from 1999 through 2019 and examine the effect of the National Center for Biotechnology Information (NCBI) Pathogen detection program of source tracking WGS isolates collected in the U.S. on outbreak illnesses for three pilot pathogens (E. coli, Listeria, and Salmonella). Empirical results are consistent with the theoretical model and suggest that each additional 1,000 WGS isolates added to the public NCBI database is associated with a reduction of approximately 6 illnesses per WGS pathogen, per year. Empirical results are connected to existing literature for a Monte Carlo analysis to estimate benefits and costs. By 2019, annual health benefits are estimated at nearly $500 million, compared to an approximately $22 million investment by public health agencies. Even under conservative assumptions, the program likely broke even in its second year of implementation and could produce increasing public health benefits as the GenomeTrakr network matures. Public Library of Science 2021-10-06 /pmc/articles/PMC8494326/ /pubmed/34614029 http://dx.doi.org/10.1371/journal.pone.0258262 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Brown, Brad
Allard, Marc
Bazaco, Michael C.
Blankenship, Joseph
Minor, Travis
An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
title An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
title_full An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
title_fullStr An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
title_full_unstemmed An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
title_short An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
title_sort economic evaluation of the whole genome sequencing source tracking program in the u.s.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494326/
https://www.ncbi.nlm.nih.gov/pubmed/34614029
http://dx.doi.org/10.1371/journal.pone.0258262
work_keys_str_mv AT brownbrad aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus
AT allardmarc aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus
AT bazacomichaelc aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus
AT blankenshipjoseph aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus
AT minortravis aneconomicevaluationofthewholegenomesequencingsourcetrackingprogramintheus
AT brownbrad economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus
AT allardmarc economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus
AT bazacomichaelc economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus
AT blankenshipjoseph economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus
AT minortravis economicevaluationofthewholegenomesequencingsourcetrackingprogramintheus